A new study examining real-world hospital data reveals early indicators of who is most likely to benefit from Cobenfy, the first new schizophrenia drug mechanism approved in 50 years.

LB Pharmaceuticals aims to show that what is old can become new again with a lead drug candidate that’s a modified version of a decades-old schizophrenia medication from Sanofi. The strategy is ...

An update from Luye Pharma Group ( ($HK:2186) ) is now available. Luye Pharma Group Ltd. has received FDA clearance to initiate clinical trials in ...

The company's drug LYBALVI, approved for adults with Schizophrenia and bipolar I disorder, shows potential for label expansion to include pediatric patients to potentially boost revenue growth. The ...

Cognision, provider of advanced neurobiomarker technology, announces its partnership with Kynexis to utilize the COGNISION(R) System in Kynexis' Phase 2 clinical trial of KYN-5356 in subjects with ...

Cobenfy, the first new schizophrenia drug in 50 years, offers early insights that could pave the way for more personalized psychosis treatment.

For many patients with schizophrenia, other psychiatric illnesses, or diseases such as hypertension and asthma, it can be difficult to take their medicine every day. To help overcome that challenge, ...

Schizophrenia, a psychiatric disorder that affects how a person feels, thinks, and behaves, affects roughly 1% of the ...

Scientists have discovered a surprising benefit of the acne drug doxycycline: it may lower the risk of schizophrenia. Teens prescribed the antibiotic were about one-third less likely to develop the ...